Forma Therapeutics Holdings, Inc.

Forma Therapeutics Holdings, Inc. (FMTX) priced its initial public offering on Jun 22, 2020 at $20.00 per share, above its $16.00–$18.00 range, raising $277.6M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $729.9M. Jefferies was lead-left underwriter, joined by Leerink Partners and Credit Suisse. Goodwin Procter advised the company and WilmerHale advised the underwriters.

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics for rare hematologic diseases and cancers. Its two core candidates are FT-4202 for sickle cell disease and FT-7051 for metastatic castration-resistant prostate cancer, from a pipeline of six candidates.

Status

IPO

Ticker

FMTX

Exchange

Nasdaq Global Market

Priced

Jun 22, 2020

IPO price

$20.00

Price range

$16.00–$18.00

Raised

$277.6M

Market cap at IPO price

$729.9M

First filed

May 29, 2020

Underwriters

Jefferies, Leerink Partners and Credit Suisse

Company counsel

Goodwin Procter

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.